Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function
- 31 March 2006
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 151 (3), 745-753
- https://doi.org/10.1016/j.ahj.2005.06.017
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney diseaseAmerican Journal of Kidney Diseases, 2005
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004
- Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline CharacteristicsKidney and Blood Pressure Research, 2004
- Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patientsKidney International, 2003
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patientsKidney International, 2002
- Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiencyKidney International, 1999
- Inflammation enhances cardiovascular risk and mortality in hemodialysis patientsKidney International, 1999
- Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosisThe Lancet, 1992
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976